Frizzled A, a novel angiogenic factor: Promises for cardiac repair

European Journal of Cardio-thoracic Surgery

Volumn 25, Issue 1, 2004, Pages 76-83

  Barandon, Laurent ^a,b   Couffinhal, Thierry ^a,b   Dufourcq, Pascale ^b   Ezan, Jérome ^b   Costet, Pierre ^c   Daret, Danièle ^b   Deville, Claude ^a   Duplàa, Cécile ^b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Gene therapy; Inflammatory cell; Myocardial infarction

Indexed keywords

ANGIOGENIC FACTOR; FRIZZLED A PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CAPILLARY DENSITY; CELL INFILTRATION; CONFERENCE PAPER; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY LIGATION; DISEASE MODEL; FUNCTIONAL ASSESSMENT; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART RUPTURE; INCIDENCE; INFLAMMATION; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCAR; TRANSGENIC MOUSE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CICATRIX; HEART RUPTURE, POST-INFARCTION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0347364739     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(03)00506-2     Document Type: Conference Paper

References (25)

1. Cleutjens J.P., Blankesteijn W.M., Daemen M.J., Smits J.F. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res. 44:(2):1999;232-241.
2. Bhanot P., Brink M., Samos C.H., Hsieh J.C., Wang Y., Macke J.P., Andrew D., Nathans J., Nusse R. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 382:(6588):1996;225-230.
3. Rattner A., Hsieh J.C., Smallwood P.M., Gilbert D.J., Copeland N.G., Jenkins N.A., Nathans J. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA. 94:(7):1997;2859-2863.
4. Duplaa C., Jaspard B., Moreau C., D'Amore P.A. Identification and cloning of a secreted protein related to the cysteine-rich domain of frizzled. Evidence for a role in endothelial cell growth control. Circ Res. 84:(12):1999;1433-1445.
5. Jaspard B., Couffinhal T., Dufourcq P., Moreau C., Duplaa C. Expression pattern of mouse sFRP-1 and mWnt-8 gene during heart morphogenesis. Mech Dev. 90:(2):2000;263-267.
6. Mao C., Malek O.T., Pueyo M.E., Steg P.G., Soubrier F. Differential expression of rat frizzled-related frzb-1 and frizzled receptor fz1 and fz2 genes in the rat aorta after balloon injury. Arterioscler Thromb Vasc Biol. 20:(1):2000;43-51.
7. Blankesteijn W.M., Essers-Janssen Y.P., Verluyten M.J., Daemen M.J., Smits J.F. A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart. Nat Med. 3:(5):1997;541-544.
8. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., Richardson J.A., Hill J.A., Olson E.N. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 99:(2):2002;907-912.
9. Schumann H., Holtz J., Zerkowski H.R., Hatzfeld M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res. 45:(3):2000;720-728.
10. Dufourcq P., Couffinhal T., Ezan J., Barandon L., Moreau C., Daret D., Duplaa C. FrzA, a secreted frizzled related protein, induced angiogenic response. Circulation. 106:(24):2002;3097-3103.
11. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 72:(2):1985;406-412.
12. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., Isner J.M. Mouse model of angiogenesis. Am J Pathol. 152:(6):1998;1667-1679.
13. Yu Z., Redfern C.S., Fishman G.I. Conditional transgene expression in the heart. Circ Res. 79:(4):1996;691-697.
14. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 53:(1):2002;31-47.
15. Cleutjens J.P. The role of matrix metalloproteinases in heart disease. Cardiovasc Res. 32:(5):1996;816-821.
16. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., Crawford J., Black S., Libby P., Mitchell P.G., Lee R.T. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 105:(6):2002;753-758.
17. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., Dyspersin G.D., Cleutjens J.P., Shipley M., Angellilo A., Levi M., Nube O., Baker A., Keshet E., Lupu F., Herbert J.M., Smits J.F., Shapiro S.D., Baes M., Borgers M., Collen D., Daemen M.J., Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 5:(10):1999;1135-1142.
18. Nelissen-Vrancken H.J., Debets J.J., Snoeckx L.H., Daemen M.J., Smits J.F. Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation. 93:(2):1996;349-355.
19. Huwer H., Welter C., Ozbek C., Seifert M., Straub U., Greilach P., Kalweit G., Isringhaus H. Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur J Cardiothorac Surg. 20:(6):2001;1128-1134.
20. Sato K., Laham R.J., Pearlman J.D., Novicki D., Sellke F.W., Simons M., Post M.J. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg. 70:(6):2000;2113-2118.
21. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., Hachamovitch R., Szulc M., Kligfield P.D., Okin P.M., Hahn R.T., Devereux R.B., Post M.R., Hackett N.R., Foster T., Grasso T.M., Lesser M.L., Isom O.W., Crystal R.G. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 100:(5):1999;468-474.
22. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., West A., Rade J.J., Marrott P., Hammond H.K., Engler R.L. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 105:(11):2002;1291-1297.
23. Dzau V.J., Mann M.J., Ehsan A., Griese D.P. Gene therapy and genomic strategies for cardiovascular surgery: the emerging field of surgiomics. J Thorac Cardiovasc Surg. 121:(2):2001;206-216.
24. Baudet E. Cardiac surgery in the 21st century: the future is now? Eur J Cardiothorac Surg. 14:(6):1998;545-553.
25. Sellke F.W., Ruel M. Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg. 75:(2):2000;S685-S690.